Additionally, PDE10A inhibition by baricitinib is hypothesized to have a synergistic pharmacological effect in combination with other COVID-19 treatments (e.g., antiviral and corticosteroids drugs) due to the anti-fibrotic and anti-inflammatory effects of phosphodiesterase’s inhibitors on the treatment of COVID-19 and its associated conditions (e.g., thrombosis, inflammation, and fibrosis)71,72. The gene discussed is PDE10A; the disease is COVID-19.